- mehrmals pro WocheErscheinungsrhythmus
- 50 mintypische Länge
- vor 5 Tagenletzte Folge
Folgenzu den neuesten
Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Cana
Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors
Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications her
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and D
Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here (https://www.researchtopract
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME in
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The Univer
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason
Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD (https://www.researchtopractice.com/ONU25/MM) information and select publications here.
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu
Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here (https://www.researchtopractice.co
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients
Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here (https://www.resear
Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma
For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory Universit
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations
Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here (https://w
Multiple Myeloma — Optimizing the Selection of First-Line Therapy
Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. CME information and select publications here (https://www.researchtopractice.com/FirstLineThe
Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies f
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress
Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent a
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasc
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress
Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Cait
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress
Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here (https://www.researchtopractice.com/OncologyToday
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Tex
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances
Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data i
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patie
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis. CME information and select publications here (https://www.researchtopractice.com/GMO25).
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of multiple myeloma. CME information and select publications here (https://www.researchtopractice.com/GMO25).
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here (https://www.re
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here (https://www.researchtopractice.
Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent
Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies
Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME info
Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/GMO25).
